Mercier Julien, Kastler Adrian, Jean Betty, Souteyrand Georges, Chabert Emmanuel, Claise Béatrice, Pereira Bruno, Gabrillargues Jean
Department of Neuroradiology, CHU Gabriel-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France.
Department of Neuroradiology, CHU Gabriel-Montpied, 58, rue Montalembert, 63003 Clermont-Ferrand cedex 1, France.
J Neuroradiol. 2015 Jul;42(4):229-35. doi: 10.1016/j.neurad.2014.02.007. Epub 2014 Nov 15.
Central retinal artery occlusion (CRAO) is a rare disease with poor visual prognosis. We evaluated clinical effectiveness of in situ fibrinolysis with original angiographic scores describing the aspect of carotid siphon, proximal ophthalmic artery, and choroid blush.
Retrospective study of 16 consecutive cases of CRAO between 2007 and 2013. Fourteen underwent in situ fibrinolysis, two were excluded due to pre-occlusive internal carotid stenosis on pre-procedural diagnostic angio-CT. Fibrinolysis was performed with rt-PA (average injected dose: 35 mg), with an average onset delay of 8hours (4-17h). We reported angiographic scores pre- and post-fibrinolysis, visual acuity (VA) before and after treatment, and VA improvement evaluated by ophthalmologist 6 to 12 months after thrombolysis.
Six patients (43%) recovered post-fibrinolysis VA significally improved, superior or equal to 1/10 (1/10 to 8/10). An irregular carotid siphon (2 cases) appeared as a predictive factor of failure. Fibrinolysis procedure led to a significant improvement of angiographic permeability of proximal ophthalmic artery (P=0.0498), but this result was not accompanied by any VA improvement. The aspect of choroid blush showed no correlation with the management of thrombolysis.
In situ fibrinolysis was more effective than medical treatments or natural evolution of CRAO (VA improvement was respectively 40% and 20%). However, the benefit/risk ratio must be discussed, and an angio-CT of supra-aortic trunks could be systematically performed before thrombolysis, to assess the potential VA recovery compared with complications such as ischemic stroke.
视网膜中央动脉阻塞(CRAO)是一种罕见疾病,视力预后较差。我们通过描述颈动脉虹吸部、眼动脉近端和脉络膜充盈情况的原始血管造影评分,评估原位纤溶治疗的临床效果。
对2007年至2013年期间连续16例CRAO患者进行回顾性研究。14例接受原位纤溶治疗,2例因术前诊断性血管造影CT显示闭塞前颈内动脉狭窄而被排除。使用重组组织型纤溶酶原激活剂(rt-PA)进行纤溶治疗(平均注射剂量:35mg),平均发病延迟时间为8小时(4 - 17小时)。我们记录了纤溶治疗前后的血管造影评分、治疗前后的视力(VA),以及溶栓后6至12个月由眼科医生评估的视力改善情况。
6例患者(43%)纤溶治疗后视力显著改善,视力优于或等于1/10(1/10至8/10)。不规则的颈动脉虹吸部(2例)表现为治疗失败的预测因素。纤溶治疗导致眼动脉近端血管造影通透性显著改善(P = 0.0498),但这一结果并未伴随任何视力改善。脉络膜充盈情况与溶栓治疗效果无关。
原位纤溶治疗比CRAO的药物治疗或自然转归更有效(视力改善率分别为40%和20%)。然而,必须讨论其获益/风险比,并且在溶栓前可系统地进行主动脉弓干血管造影CT,以评估与缺血性中风等并发症相比潜在的视力恢复情况。